TypeOneNation attendees should be on the lookout for the Type 1 Diabetes TrialNet (TrialNet) screening area on Saturday, February 25^th. The TrialNet Chicagoland team will be on-site at the Breakthrough T1D TypeOne Nation Summit to test family members of those with type 1 diabetes (T1D) for diabetes-related antibodies.

Participating in TrialNet is easy! Stop by the TrialNet booth in the Wellness Area for a simple blood test. That’s all it takes!

Did you know that if you have a relative with T1D, you are at a 15 times greater risk of developing it yourself? The TrialNet Pathway to Prevention is a Breakthrough T1D-sponsored study that monitors people at increased risk for type 1 diabetes. TrialNet’s goal is to learn more about how T1D occurs and delay or prevent its onset.

Participating in this important research helps us get closer to a cure.  There is no cost to you for this screening.

If you have any questions about the process, please do not hesitate to contact Gail Gannon at ggannon@uchicago.edu or 773-702-3853.

Background:

TrialNet is an international network of researchers who are exploring ways to prevent, delay, and reverse the progression of type 1 diabetes (T1D).  The first phase of TrialNet is screening which involves a blood test for relatives of people with T1D. The blood test will see if diabetes related auto-antibodies are present.  These auto-antibodies are proteins made by the body’s immune system and indicate increased risk of developing T1D. This screening test is the first phase of the TrialNet Pathway to Prevention.

Participants will be notified of results within 4-6 weeks after your blood sample is received.  If the results are negative (no auto-antibodies), you will receive a letter.  If results are positive, you will be contacted by phone to discuss further optional testing.

For more information about Trial Net, please visit: https://www.diabetestrialnet.org/

To register or learn more about TypeOneNation, click here.